Fimasartan

Fimasartan is associated with major adverse cardiovascular events in humans (Adjusted HR 0.895, 95% CI 0.796–1.006; p = 0.0628).

“fimasartan was associated with a numerically lower MACE risk than CCBs, although the 95% confidence interval included the null value”

HumansHypertension without prior cardiovascular disease; treatment-naïve new users; comparison with calcium channel blockersmonotherapy3 years

Comparative Cardiovascular Outcomes of Fimasartan and Calcium Channel Blockers in Hypertension: A Nationwide 3-Year Follow-Up Cohort Study

Journal of clinical medicine·3 Oct 2026